Navigation Links
How is H pylori adhesion to gastric cells associated with MUC1 mucin VNTR size?
Date:3/18/2008

The Gram negative bacterium H pylori is involved in the pathogenesis of several gastrointestinal diseases, ultimately leading to gastric carcinoma. Adhesion of the bacteria to the gastric mucosa is an essential step for colonization and infection.

It is therefore important to know factors that influence the binding of the bacteria to gastric cells. MUC1, a mucin with a highly variable repetitive region (VNTR), has been recently identified as an H pylori binding target. In this work we tested the hypothesis that MUC1 VNTR polymorphism affects H pylori adhesion to gastric cells and thus plays an important role in the colonization of gastric mucosa.

Enzyme linked immunosorbent assay (ELISA)-based adhesion assays were performed to measure the adhesion of different H pylori strains (HP26695 and HPTx30a) to gastric carcinoma cell lines (GP202 and MKN45) and GP202 clones expressing recombinant MUC1 with different VNTR lengths. The research article to be published on March 7, 2008 in the World Journal of Gastroenterology.

The results showed that MUC1 VNTR polymorphism influences the binding of H pylori to gastric cells, with the higher adhesion levels observed in clones with larger VNTR regions. Furthermore, higher adhesion was observed in co-cultures with the pathogenic strain (HP26695) when compared to the non-pathogenic strain (HPTx30a) and GP202 cell line when compared to the MKN45 cell line. This work contributes to the understanding of the interplay between host and bacterial factors in H pylori infection pathogenesis.


'/>"/>

Contact: Jing Zhu
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. A low prevalence of H pylori in HIV-positive patients
2. Helicobacter pylori inhibits intercellular communication of cultured gastric cells
3. FDA Panel Recommends Approval of SyntheMeds REPEL-CV(R) Adhesion Barrier for Pediatric Patients
4. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
5. MetaCure(TM) Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight
6. EndoGastric Solutions Opens Three Training Centers to Keep Up with Demand from Surgeons Wanting to Learn StomaphyX(TM) Procedures
7. Gastric cancer survivors should be aware of osteoporosis
8. Gastric Lap-Band Surgery Can Send Diabetes Into Remission
9. Optimal band imaging with endoscopy facilitates the diagnosis of depressed-type early gastric cancer
10. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
11. Brain cells work differently than previously thought
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... director. Mr. Still was selected through a careful months-long search by the RBMA Board ... to our members, has been a part of building the RBMA since 1992,” said ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... release of two biometric time and attendance tracking products: the new NCheck Cloud ... NCheck Cloud Bio Attendance uses biometric face recognition to enable users to check ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Executives, Staff & Clients ... to for the Toys for Tots Literacy Campaign at their Semi-Annual Graduation and Fundraiser ... $70 billion, the U.S. ranks at number 14 internationally in literacy. Statistically, a direct ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... SkyLex Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon ... this procedure adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Silicon Valley Hair ... to announce a new blog post about women’s hair loss. Although hair transplant procedures ... loss as they age. Menopause or genetics can be two reasons a woman may ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... REDWOOD CITY, Calif. , March 28, 2017 ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that the European Medicines Agency ... (sufentanil sublingual tablet, 30 mcg) Marketing Authorisation Application ... review of the MAA is underway. The MAA ...
(Date:3/28/2017)... 28, 2017 RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Japan Patent Office (JPO) for the composition of ... (CTGF) for the treatment or prevention of fibrotic ... and proliferative retinopathy (Japanese Patent #: 6060071).  This ...
(Date:3/28/2017)... , March 28, 2017 ... to reach USD 8.0 billion by 2025, according to ... increasing incidence of infectious diseases and cancer is expected ... in disease diagnosis over the coming years. In addition, ... of autologous and allogenic stem cell therapy, due to ...
Breaking Medicine Technology: